Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and…

• NS
  National Science Foundation
• A
  Amgen
• AA
  American Academy of Allergy Asthma and Immunology
• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• TP
  Teva Pharmaceutical Industries
• D
  Danone
• UL
  Université Laval
• ER
  European Respiratory Society
• S
  Sunovion
• RP
  Regeneron Pharmaceuticals
• CT
  Canadian Thoracic Society
• IT
  Immune Tolerance Network
• IO
  Institute of Science and Technology Austria
• UO
  University of Sharjah
• FS
  Food Standards Agency
• IC
  Imperial College London
• IC
  Imperial College Healthcare NHS Trust
• EC
  European Commission
• UO
  University of Glasgow
• UC
  University College Cork
• SN
  Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
• CS
  China Scholarship Council
• S
  Servier
• EA
  European Academy of Allergy and Clinical Immunology
• G
  Genentech
• A
  Allergan
• SO
  School of Medicine and Public Health, University of Wisconsin-Madison
• A
  Allergopharma
• MR
  Medical Research Council
• HS
  Helse Sør-Øst RHF
• NI
  National Institute of Allergy and Infectious Diseases